HUBACEK, Jaroslav A., Ladislav DUŠEK, Ondřej MÁJEK, Vaclav ADAMEK, Tereza CERVINKOVA, Dana DLOUHA, Jozef PAVEL and Vera ADAMKOVA. CCR5 Delta 32 Deletion as a Protective Factor in Czech First-Wave COVID-19 Subjects. Physiological research. Praha: Fyziologický ústav AV ČR, 2021, vol. 70, No 1, p. 111-115. ISSN 0862-8408. Available from: https://dx.doi.org/10.33549/physiolres.934647.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name CCR5 Delta 32 Deletion as a Protective Factor in Czech First-Wave COVID-19 Subjects
Authors HUBACEK, Jaroslav A. (203 Czech Republic, guarantor), Ladislav DUŠEK (203 Czech Republic, belonging to the institution), Ondřej MÁJEK (203 Czech Republic, belonging to the institution), Vaclav ADAMEK (203 Czech Republic), Tereza CERVINKOVA (203 Czech Republic), Dana DLOUHA (203 Czech Republic), Jozef PAVEL (203 Czech Republic) and Vera ADAMKOVA (203 Czech Republic).
Edition Physiological research, Praha, Fyziologický ústav AV ČR, 2021, 0862-8408.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30105 Physiology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.139
RIV identification code RIV/00216224:14110/21:00121769
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.33549/physiolres.934647
UT WoS 000631146600011
Keywords in English COVID-19; CCR5; Polymorphism; Deletion; Delta 32
Tags 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 15/6/2021 07:49.
Abstract
Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease (COVID-19), has spread widely around the globe. Significant inter-individual differences have been observed during the course of the infection, which suggests that genetic susceptibility may be a contributing factor. CC chemokine receptor 5 (CCR5), which acts as a co-receptor for the entry of HIV-1 into cells, is promising candidate whose can have an influence on SARS-CoV-2 infection. A genetic mutation known as CCR5 Delta 32, consisting of a 32-nucleotide deletion, encodes a truncated protein that protects homozygous carriers of the deletion from HIV-1 infection. Similarly, inhibition of CCR5 seems to be protective against COVID-19. In our study, we successfully genotyped 416 first-wave SARS-CoV-2-positive infection survivors (164 asymptomatic and 252 symptomatic) for CCR5 Delta 32, comparing them with a population based sample of 2,404 subjects. We found the highest number (P=0.03) of CCR5 Delta 32 carriers in SARS-CoV-2-positive/COVID-19-asymptomatic subjects (23.8 %) and the lowest number in SARS-CoV-2-positive/COVID-19-symptomatic patients (16.7 %), with frequency in the control population in the middle (21.0 %). We conclude that the CCR5 Delta 32 I/D polymorphism may have the potential to predict the severity of SARS-CoV-2 infection.
PrintDisplayed: 27/7/2024 20:17